In a prospective study infants born to mothers with epilepsy (n=61) were found to have an unexpectedly high incidence of congenital anomalies (26/61, 43%) and neonatal conditions (26/61, 43%) compared with controls (0/62, and 6/62, 10%, respectively). There were two neonatal deaths in the study group but none among the controls. Hypoplasia of the finger or toenails was a common congenital anomaly in those infants whose mothers had received phenytoin alone or in combination with other anticonvulsant drugs (11 of 40, 28%). The mean serum phenytoin concentration was higher among mothers of infants with hypoplastic nails than among those with normal nails. Jitteriness was a common neonatal condition affecting infants of epileptic mothers (11 of 61, 18%) but not controls. The mean cord serum phenytoin concentrations were similar among jittery and nonjittery infants. At follow up (after excluding one infant with Down's syndrome from the study group) the infants seemed to have developed normally, though one had serious learning difficulties at school. We suggest that hypoplasia of the nails is related to high maternal serum concentrations of phenytoin, and though 18% of infants born to epileptic mothers were jittery compared with no control infants this may not be the result of withdrawal of the drug in all cases.
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tal anomalies and neonatal conditions in infants born to epileptic mothers were compared with those in a control group born to mothers without epilepsy. Hypoplasia of the finger and toenails and jitteriness, which were commonly seen in infants of epileptic mothers, were related to phenytoin concentrations in maternal blood and cord blood, respectively. Infants of epileptic mothers and of controls were followed up at outpatient clinics. 6 'The minor congenital anomalies include hypoplastic nails, distal phalangeal hypoplasia, epicanthic folds, hypertelorism, long philtrum, abnormal ears, and low hairline.4 A combination of some of these features associated with microcephaly, growth deficiency, and mental retardation has been identified in infants of mothers treated with phenytoin and has been called the 'fetal hydantoin syndrome'.7 Though exposure to anticonvulsant drugs has been suggested as a cause of these anomalies3 8 9 some of them may be genetically linked to epilepsy. 4 Various neonatal conditions have been described in infants born to epileptic mothers, including irritability,2 gingival hyperplasia,2 and haemorrhage as a result of a coagulation defect. 12 The irritability may have been a symptom of withdrawal of the drug at birth. '3 In the present study the incidence of congeni-
ANTICONVULSANT DRUGS
Maternal serum drug concentrations were maintained within therapeutic ranges for phenytoin Fetal phenytoin exposure, ypolastic nails, andjitteriness 
Flattened bridge of nose and hypertelorism
Transverse palmar crease - Most of the infants had minor congenital abnormalities (table 2), though there were some children with major defects. One infant born to a 29 year old mother who had phenytoin throughout pregnancy had Down's syndrome. Five infants had congenital heart disease in the form of atrial septal defect (n=2), ventricular septal defect (n=1), patent ductus arteriosus (n=-), and hypoplastic left heart syndrome (n=l). Two infants had cranial nerve palsy. One infant with a right facial palsy and hypoglossal nerve palsy had been exposed to carbamazepine throughout pregnancy and was born by caesarean section. The other infant with bilateral abducent nerve palsy (associated with a patent ductus arteriosus) was born to a mother who had been taking phenobarbitone throughout pregnancy.
Hypoplasia of nails was more common than any other congenital anomaly (table 2), 11 infants (18%) being affected. Hypoplastic nails were recorded if several finger or toenails were small, brittle, and deeply set with an irregular surface and yellow discoloration. Hypoplasia of the fifth toenail, which is a common finding among newborn babies, was not recorded. All the infants with hypoplastic nails had been exposed to phenytoin in the uterus (in five it was the only drug and in six it was in combination with other anticonvulsant drugs). Infants born to epileptic mothers who were taking anticonvulsant drugs other than phenytoin, or those born to similar mothers who had not received anticonvulsant drugs, did not have hypoplastic nails (table 3) . Some infants had hypoplastic nails alone, while others had hypoplastic nails in combination with other congenital anomalies including distal phalangeal hypoplasia, flattened bridge of the nose and hypertelorism, congenital heart disease, inguinal hernia, and transverse palmar crease. Feeding difficulty (tube fed) -, Absence of a particular neonatal condition.
Among those mothers who had taken phenytoin (alone or in combination with other drugs) there was no significant difference in the mean (SD) cord blood serum phenytoin concentrations between infants with jitteriness (16-3 (7-0) mg/I, n=11) and those without jitteriness (15-7 (7-8) mg/I, n=25). All the jittery infants were in a good condition at birth and none had had birth asphyxia. One jittery infant developed tonic and clonic seizures on day 2 as a result of hypocalcaemia (serum calcium concentration 09 mmol/l). There were two neonatal deaths (at 21 hours and 28 hours of age) among infants of mothers with epilepsy. The first infant was born preterm at 32 weeks' gestational age and had idiopathic respiratory distress and pneumothorax. The second infant was born at a similar gestational age and had intrauterine growth retardation and congestive heart failure caused by a hypoplastic left heart. FOLLOW UP Among infants with hypoplastic nails at birth, improved nail growth had taken place by 3 months of age. The jitteriness that was observed during the first three days of birth had resolved by 2 weeks. Excluding the child with Down's syndrome, none of the remaining children in the study group had a major impairment in later childhood. There were therefore no children with neuromotor impairment caused by cerebral palsy and none with sensorineural hearing loss, impaired vision, epilepsy, or developmental delay. The median (range) developmental quotients of the children of epileptic mothers (excluding the child with Down's syndrome) and of controls were 94 (75-134) and 98 (90-120), respectively. With the exception of the child with Down's syndrome (who attended a special school) the children in both groups attended normal schools. One child in the study group received special help at school for serious learning difficulties; he also had some dysmorphic features including a flattened bridge of the nose and hypertelorism.25 These findings were associated with severe reading and spelling difficulty, impaired language development, and visuospatial defects.
Discussion
The high incidence of congenital anomalies in the present study (43%) is nearly four times that mentioned in a review of previous prospective studies of infants born to epileptic mothers.6 This unexpected result may be the result of dif ferences in the methods of assessment an reporting of congenital anomalies. Alterna tively, the differences might have arisen becausj of the way we managed anticonvulsant drugs during pregnancy; doses were increased as gestational age advanced to maintain serum concentrations of phenytoin, phenobarbitone, and carbamazepine within a 'therapeutic range' and to reduce the risk of epileptic fits during pregnancy. This could, however, have influenced fetal growth and development only in the second and third trimesters of pregnancy.
Because organogenesis during the first trimester would not have been affected we had expected the incidence of congenital anomalies to be similar to that previously reported. It has been suggested that folate supplements may have a protective effect if the teratogenic effect of anticonvulsants is caused by folate antagonism.5 In our study it is doubtful whether giving such supplements was of any benefit, either because folic acid was prescribed too late or because the congenital abnormalities were not mediated by folate antagonism.
Most of the congenital anomalies we observed are common among infants of epileptic mothers. Nevertheless, there are certain differences between this and other studies. Firstly, hypoplastic nails were more common than any other congenital anomaly in our study, while previous studies have reported medial epicanthic folds, a large anterior and posterior fontanelle, or a broad nasal bridge as being more common in such infants. 2 4 Secondly, there were no cases of orofacial clefts in the present study. In contrast, a similar anomaly had increased roughly tenfold in infants of epileptic mothers.26 Thirdly, cranial nerve anomalieswhich were found in two (3%) of our infants of epileptic mothers-have not previously been reported. The present findings have raised the possibility of agenesis of the cranial nerve nuclei as a result of fetal exposure to carbamazepine or phenobarbitone.27 Fourthly, one infant with Down's syndrome was born to a 29 year old mother in the study group. At this maternal age the incidence of liveborn infants with Down's syndrome is about 1:935 but it is not known whether the incidence is affected by maternal epilepsy or anticonvulsant treatment. 28 In the present study hypoplastic nails resulting from treatment with phenytoin in pregnancy were associated with higher mean maternal phenytoin concentrations in the second and third trimesters. It Neonatal jitteriness may result from withdrawal of the drug.'3 It was observed in our infants within a three day period of birth, and did not seem to be related to a specific drug or to cord serum phenytoin concentrations. In addition, our study has shown that jitteriness occurred in one of eight infants born to epileptic mothers who did not receive drugs during pregnancy. This raises the possibility that there are other causes of jitteriness including a reduced calcium concentration such as occurred in one infant who developed tonic and clonic seizures.
Although an increased incidence of various congenital anomalies and neonatal conditions was observed in the infants born to epileptic mothers, those infants who survived seemed to do so without major impairments though one of them had a serious learning disability. We are aware that Gaily et 
